Benidipine Hydrochloride: A Triple-Action Calcium Channel Blocker for Superior Hypertension Management – Pharmacological Insights, Analytical Techniques, and Future Perspectives

Benidipine Hydrochloride is a long-acting dihydropyridine calcium channel blocker (CCB) with a unique triple-blocking action on L-, T-, and N-type calcium channels. This distinct mechanism provides superior antihypertensive efficacy, cardiovascular protection, and renal benefits compared to conventional CCBs. Benidipine effectively lowers blood pressure by reducing peripheral vascular resistance while improving endothelial function and decreasing oxidative stress. Its ability to inhibit T-type calcium channels contributes to nephroprotection by lowering glomerular pressure and reducing proteinuria, making it particularly beneficial for patients with hypertension-related kidney disease. Additionally, N-type calcium channel blockade reduces sympathetic overactivity, leading to further stabilization of blood pressure and improved cardiac outcomes. Pharmacokinetically, Benidipine exhibits high lipophilicity, extensive plasma protein binding, and hepatic metabolism via CYP3A4, resulting in a prolonged half-life that supports once-daily dosing. Various analytical methods, including chromatographic techniques such as HPLC, UPLC, RP-HPLC, and LC-MS/MS, alongside spectroscopic techniques like UV-visible, FTIR, and NMR, are employed to assess its purity, stability, and pharmacokinetic properties. Advanced method development and validation strategies ensure regulatory compliance, drug safety, and therapeutic efficacy. This review explores Benidipine’s pharmacological profile, mechanism of action, and analytical methodologies, emphasizing its clinical significance in hypertension and cardiovascular disease management. Additionally, future trends in green chemistry and automation in pharmaceutical analysis are discussed, highlighting the evolving landscape of Benidipine research and its potential for improved therapeutic applications.